D. Solit

425 total citations
15 papers, 339 citations indexed

About

D. Solit is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, D. Solit has authored 15 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in D. Solit's work include Cancer Treatment and Pharmacology (6 papers), HER2/EGFR in Cancer Research (4 papers) and Cancer Genomics and Diagnostics (4 papers). D. Solit is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), HER2/EGFR in Cancer Research (4 papers) and Cancer Genomics and Diagnostics (4 papers). D. Solit collaborates with scholars based in United States, Spain and Australia. D. Solit's co-authors include Larry Norton, N Rosen, Andrea Basso, Pamela N. Münster, Shanu Modi, Geoffrey I. Shapiro, Cristina Saura, Sherene Loi, Funda Meric‐Bernstam and José Baselga and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

D. Solit

15 papers receiving 327 citations

Peers

D. Solit
Hannah Linden United States
Christa L. Borgman United States
Michelle S. Miller United States
Raymond M. Paranal United States
Hyo-Eun Carrie Bhang United States
Liv Johannessen United States
Susmita G. Ramanand United States
Chuanchuan Li United States
Alberto Vides United States
Zuan-Fu Lim United States
Hannah Linden United States
D. Solit
Citations per year, relative to D. Solit D. Solit (= 1×) peers Hannah Linden

Countries citing papers authored by D. Solit

Since Specialization
Citations

This map shows the geographic impact of D. Solit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Solit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Solit more than expected).

Fields of papers citing papers by D. Solit

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Solit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Solit. The network helps show where D. Solit may publish in the future.

Co-authorship network of co-authors of D. Solit

This figure shows the co-authorship network connecting the top 25 collaborators of D. Solit. A scholar is included among the top collaborators of D. Solit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Solit. D. Solit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Arora, Kanika, Vicky Makker, Darren J. Buonocore, et al.. (2024). 645P Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors. Annals of Oncology. 35. S510–S510. 1 indexed citations
2.
Friedman, Claire F., Valentina Gambardella, Sherene Loi, et al.. (2022). 559P Neratinib in HER2-mutant, recurrent/metastatic cervical cancer (R/M CC): Updated findings from the phase 2 SUMMIT basket trial. Annals of Oncology. 33. S803–S804. 1 indexed citations
3.
Janjigian, Yelena Y., Steven B. Maron, Joanne F. Chou, et al.. (2019). First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma. Annals of Oncology. 30. v313–v313. 8 indexed citations
4.
Hyman, Daniel, Sarina A. Piha‐Paul, Cristina Saura, et al.. (2017). Abstract PD2-08: Neratinib + fulvestrant in ERBB2-mutant, HER2–non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial. Cancer Research. 77(4_Supplement). PD2–8. 16 indexed citations
5.
Olshen, Adam B., et al.. (2016). Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity - eScholarship. 16 indexed citations
6.
Rodón, Jordi, Cristina Saura, Igor Puzanov, et al.. (2016). Abstract PD5-05: Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial. Cancer Research. 76(4_Supplement). PD5–5. 11 indexed citations
7.
8.
9.
Morris, Michael J., Neeta Pandit‐Taskar, Ryan D. Stephenson, et al.. (2008). Phase I study of docetaxel (Tax) and 153Sm repetitively administered for castrate metastatic prostate cancer (CMPC). Journal of Clinical Oncology. 26(15_suppl). 5001–5001. 8 indexed citations
10.
Chandarlapaty, Sarat, et al.. (2007). Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer. Journal of Clinical Oncology. 25(18_suppl). 10515–10515. 4 indexed citations
11.
Morris, Michael J., Neeta Pandit‐Taskar, Gretchen A. Gignac, et al.. (2007). Phase I study of docetaxel and 153Sm repetitively administered for castrate metastatic prostate cancer (CMPC). Journal of Clinical Oncology. 25(18_suppl). 5152–5152. 2 indexed citations
12.
Modi, Shanu, A. Stopeck, Michael S. Gordon, et al.. (2006). Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T). Journal of Clinical Oncology. 24(18_suppl). 501–501. 8 indexed citations
13.
Eiseman, Julie L., Junjie Guo, Rajesh Ramanathan, et al.. (2005). Evaluation of plasma insulin-like growth factor binding protein 2 (IGFBP-2) as a biomarker for 17-allylamino-17-demethoxygeldanamycin (17-AAG) treatment of adult patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 23(16_suppl). 2083–2083. 2 indexed citations
14.
Solit, D.. (2003). Hsp90 as a therapeutic target in prostate cancer. Seminars in Oncology. 30(5). 709–716. 114 indexed citations
15.
Münster, Pamela N., Andrea Basso, D. Solit, Larry Norton, & N Rosen. (2001). Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.. PubMed. 7(8). 2228–36. 141 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hannah Linden Breakdown of academic impact, for papers by Christa L. Borgman Breakdown of academic impact, for papers by Michelle S. Miller Breakdown of academic impact, for papers by Raymond M. Paranal Breakdown of academic impact, for papers by Hyo-Eun Carrie Bhang Breakdown of academic impact, for papers by Liv Johannessen Breakdown of academic impact, for papers by Susmita G. Ramanand Breakdown of academic impact, for papers by Chuanchuan Li Breakdown of academic impact, for papers by Alberto Vides Breakdown of academic impact, for papers by Zuan-Fu Lim
Rankless by CCL
2026